ENLV - Enlivex Therapeutics Ltd.

0.89
0.002   0.225%

Share volume: 81,439
Last Updated: 04-07-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.00%

PREVIOUS CLOSE
CHG
CHG%
$0.89
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
25%
Profitability 25%
Dept financing 5%
Liquidity 50%
Performance 25%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.96%
1 Month
-23.28%
3 Months
-24.58%
6 Months
-39.86%
1 Year
-78.29%
2 Year
-70.82%
Key data
Stock price
$0.89
P/E Ratio 
0.00
DAY RANGE
$0.86 - $0.92
EPS 
-$0.24
52 WEEK RANGE
$0.81 - $4.19
52 WEEK CHANGE
-$78.19
MARKET CAP 
27.133 M
YIELD 
N/A
SHARES OUTSTANDING 
20.872 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
2.08
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$91,897
AVERAGE 30 VOLUME 
$123,555
Company detail
CEO: Oren Hershkovitz
Region: US
Website: enlivex.com
Employees: 70
IPO year: 2009
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state.

Recent news
loading